September 05, 2025

Extended-Release Risperidone Injection Receives FDA Approval

FDA approves Amneal’s risperidone extended-release injection for schizophrenia and Bipolar I maintenance.

Conexiant

September 03, 2025

Policy Shift Adjusts NIH Peer Review Role

New NIH funding rules shift decision-making power from peer review panels to political appointees in determining future scientific grants.

KFF Health News

September 02, 2025

New Maintenance Option for Early Alzheimer’s Approved by FDA

FDA approves Leqembi IQLIK (lecanemab-irmb), a once-weekly subcutaneous autoinjector for maintenance treatment of early Alzheimer’s disease.

Conexiant

August 27, 2025

Remission Patterns in Youth at Risk for Psychosis

When participants had at least 1 follow-up visit after achieving remission, the likelihood of staying in remission increased. 

Conexiant

August 20, 2025

Electroencephalography Measures Linked to Schizophrenia

Researchers link gamma-band power, alpha shifts to schizophrenia markers.

Conexiant

August 13, 2025

AI Device Approval for Dementia Lacks Diversity

Most FDA-authorized artificial intelligence devices for Alzheimer disease lack transparent demographic data.

Conexiant

May 09, 2024

Time of Day May Impact Aging Predictions

New study reveals that epigenetic age predictions fluctuate significantly throughout the day, emphasizing the need to consider timing in aging assessments.

Conexiant

February 06, 2025

Meds that May Increase Dementia Risk

Antimicrobials, anti-inflammatories, and vaccines were associated with reduced dementia risk, while antipsychotics, antidepressants, and diabetes medications were frequently associated with increased dementia risk.

Conexiant

April 28, 2025

One Third Report HPPD After Psychedelics

Delusional ideation was found to be reduced one month after psychedelic use, researchers reported in a prospective cohort of 654 participants.

Conexiant